IMPACT OF VTE ON COVID-19-RELATED HOSPITALIZATION: A RETROSPECTIVE ANALYSIS

Abstract

SESSION TITLE: Studies on COVID-19 Abstract PostersSESSION TYPE: Original InvestigationsPRESENTED ON: 10/18/2022 02:45 pm - 03:45 pmPURPOSE: Early data have suggested that venous thromboembolism (VTE) is associated with increased morbidity and mortality in patients suffering from acute respiratory distress syndrome (ARDS) related to coronavirus disease 2019 (COVID-19). The purpose of this study is to find the true impact of developing VTE on the outcomes of COVID-19 related hospitalization.METHODS: In this retrospective study, we have analyzed the effect of VTE on COVID-19 related hospitalization in a cohort of patients admitted in our hospital between March 2020 to February 2021. Patients were identified who were admitted with a primary diagnosis of COVID-19. We then looked for the patients who developed pulmonary embolism and deep venous thrombosis (VTE) as a complication. Patients were divided into two groups and compared: those who developed VTE (VTE group) and those who didn’t develop VTE (non-VTE group). The primary outcome of our study is in-hospital mortality whereas, secondary outcomes were critical care unit (CCU) stay and overall length of stay.RESULTS: A total of 1448 patients were identified. Out of which 43 patients were found to have VTE, or 3.07%. We found that VTE group patients had a 28-day mortality of 23% versus 16% in non-VTE group, P>0.05. Our results also revealed that patients with VTE have 98% higher odds of likely requiring CCU stay during the course of their hospitalization, odds ratio 1.98 (CI 1.08-3.65, P<0.05). Furthermore, the median length of stay was noted to be marginally higher among VTE group vs. non-VTE group COVID-19 patients (6 days vs. 5 days, respectively), P>0.05.CONCLUSIONS: VTE is associated with higher mortality and longer length of stay among COVID-19 patients, but our results were not statistically significant. However, statistically significant association is noted with regards to higher risk of requiring CCU stay during hospitalization.CLINICAL IMPLICATIONS: This analysis reinforces the latest guidlines on the use of anti-coagulation in COVID-19 patients. However, further studies are warranted to support its benefits in such patient population.DISCLOSURES: No relevant relationships by William BancroftNo relevant relationships by Devesh DahaleNo relevant relationships by Awais FarooqNo relevant relationships by Adnan LiaqatNo relevant relationships by Sebastian Thomas Tosto MDNo relevant relationships by Arash Velayati SESSION TITLE: Studies on COVID-19 Abstract Posters SESSION TYPE: Original Investigations PRESENTED ON: 10/18/2022 02:45 pm - 03:45 pm PURPOSE: Early data have suggested that venous thromboembolism (VTE) is associated with increased morbidity and mortality in patients suffering from acute respiratory distress syndrome (ARDS) related to coronavirus disease 2019 (COVID-19). The purpose of this study is to find the true impact of developing VTE on the outcomes of COVID-19 related hospitalization. METHODS: In this retrospective study, we have analyzed the effect of VTE on COVID-19 related hospitalization in a cohort of patients admitted in our hospital between March 2020 to February 2021. Patients were identified who were admitted with a primary diagnosis of COVID-19. We then looked for the patients who developed pulmonary embolism and deep venous thrombosis (VTE) as a complication. Patients were divided into two groups and compared: those who developed VTE (VTE group) and those who didn’t develop VTE (non-VTE group). The primary outcome of our study is in-hospital mortality whereas, secondary outcomes were critical care unit (CCU) stay and overall length of stay. RESULTS: A total of 1448 patients were identified. Out of which 43 patients were found to have VTE, or 3.07%. We found that VTE group patients had a 28-day mortality of 23% versus 16% in non-VTE group, P>0.05. Our results also revealed that patients with VTE have 98% higher odds of likely requiring CCU stay during the course of their hospitalization, odds ratio 1.98 (CI 1.08-3.65, P<0.05). Furthermore, the median length of stay was noted to be marginally higher among VTE group vs. non-VTE group COVID-19 patients (6 days vs. 5 days, respectively), P>0.05. CONCLUSIONS: VTE is associated with higher mortality and longer length of stay among COVID-19 patients, but our results were not statistically significant. However, statistically significant association is noted with regards to higher risk of requiring CCU stay during hospitalization. CLINICAL IMPLICATIONS: This analysis reinforces the latest guidlines on the use of anti-coagulation in COVID-19 patients. However, further studies are warranted to support its benefits in such patient population. DISCLOSURES: No relevant relationships by William Bancroft No relevant relationships by Devesh Dahale No relevant relationships by Awais Farooq No relevant relationships by Adnan Liaqat No relevant relationships by Sebastian Thomas Tosto MD No relevant relationships by Arash Velayati